News | Computer-Aided Detection Software | November 08, 2017

CureMetrix Expands Medical Advisory Board

Leading radiology experts will guide company’s advancements in computer-aided diagnosis to improve mammography readings

CureMetrix Expands Medical Advisory Board

November 8, 2017 — CureMetrix, a company developing computer-aided detection (CAD) for mammography to improve clinical outcomes, recently expanded its medical advisory board. Made up of leaders in radiology from the U.S.’s top healthcare institutions, the medical advisory board contributes valuable clinical perspectives to CureMetrix’s investigational image analysis solutions leveraging artificial intelligence and deep machine learning.

CureMetrix is currently developing a physics-based software algorithm that allows radiologists to get more specific and sensitive readings of breast images from existing imaging systems.

Advisory board members will work with CureMetrix Chief Medical Officer William G. Bradley, M.D., Ph.D., and former chair of the University of California (UC) San Diego Health Department of Radiology.

CureMetrix advisory board members include:

  • Jade de Guzman, M.D., is a diagnostic radiologist at Sharp Rees-Stealy Medical Group in San Diego. She is also a voluntary assistant clinical professor at the University of California, San Diego, Department of Radiology. She completed her radiology residency and breast imaging fellowship at University of California, Los Angeles. Her main interests include all aspects of diagnostic and interventional breast radiology;
  • Curtis Duffield, M.D., is a breast imager at Sharp Rees-Stealy Medical Group in San Diego. He completed his medical training and radiology residency at University of California, Davis followed by a dedicated breast imaging fellowship at Harvard’s Massachusetts General Hospital. He has a special interest in computational methods to improve decision making and early detection of breast cancer;
  • Christopher Comstock, M.D., is the imaging co-chair of the ECOG-ACRIN Breast Committee, chair of the American College of Radiology (ACR) Committee on BI-RADS (Breast Imaging-Reporting and Data System) Breast MRI (magnetic resonance imaging), and member of the NCI Bold task force. Comstock was previously the assistant professor of radiology at the University of Chicago and Northwestern University Hospital’s Lynn Sage Breast Center. He was also chief of breast imaging at the University of California San Diego and was chair on several boards and committees, including the ACR Breast Ultrasound Accreditation program and ACRIN Institutional Participants Committee. He has co-authored a textbook on breast cancer imaging, written several book chapters, been involved in numerous breast imaging publications and has given over 400 invited lectures;
  •  Vivian Lim, M.D., is a radiologist and head of mammography overseeing the comprehensive breast imaging service she developed at four Scripps Clinical Medical Group locations in San Diego. She is a member of the Alpha Omega Alpha Medical Honor Society, the ACR, the American Roentgen Ray Society, the Radiological Society of North America (RSNA) and the San Diego County Radiologic Society. She graduated from the University of Texas Health Science Center in San Antonio, did an internal medicine internship, followed by diagnostic radiology residency and another year of fellowship in MRI, all at University of California, San Diego;
  • Jenna Liu, M.D., is a radiologist at Sharp Grossmont Hospital in San Diego. She is the vice president of X-Ray Medical Group and was previously the chair and vice chair of the Department of Radiology at Sharp Grossmont Hospital as well as president of the San Diego Radiological Society. She has a special interest in all aspects of MRI, mammography and developing tools for early detection of breast cancer;
  • Allen Nalbandian, M.D., is a radiologist at Palomar Medical Center in Escondido, Calif. He is the president of Valley Radiology Consultants and is an active member of the ACR, RSNA, the American Roentgen Ray Society and the Society of Breast Imaging. Nalbandian previously served as the president of the San Diego Radiological Society. He has a special interest in all phases of women’s imaging including mammography, breast ultrasound, breast MRI and the entire spectrum of breast interventional procedures including stereotactic, ultrasound and MRI guided breast biopsy procedures;
  •  Michele Rochelle, M.D., is board certified in diagnostic radiology with the American Board of Radiology. She received her Bachelor of Science degree from the University of California, San Diego and her medical degree from the University of California, Davis. Rochelle completed her diagnostic radiology residency at the University of California, San Diego. She then completed her Breast Imaging Fellowship at the University of Washington. She has been practicing in the San Diego area for several years and specializes in breast imaging, with a focus on early breast cancer detection through screening mammography; and
  • Alyssa Watanabe, M.D., is a clinical associate professor of radiology at the University of Southern California Keck School of Medicine. She is a nationally recognized expert in radiology with over 20 years of practice and has lectured on the topic of continuing medical education meetings. Her articles have been published in numerous leading journals like the American Journal of Radiology and she is past president of the American Society of Spine Radiology. Watanabe was previously director of breast imaging at Patricia L. Scheifly Breast Health Center in Whittier, Calif., and director of breast MRI at MemorialCare Imaging Center at Long Beach Memorial.

CureMetrix was founded in 2014 on the belief that better medical image analysis technology could lead to better outcomes for breast cancer patients. The company is developing investigational physics-based artificial intelligence and deep machine learning solutions to help radiologists get more accurate readings of breast images. Through its research partnerships with leading hospital radiology departments, CureMetrix has evaluated more than 500,000 mammogram images to identify potential false negatives, which are undiagnosed cancers, and false positives, which are unnecessary recalls of patients to review anomalies that turn out to be normal. False negatives can occur at a rate of about one in five breast cancers.1 False positives affect 7-12 percent of all women after an initial mammogram.2 Reducing false positives could save a significant portion of the $4 billion per year spent on unneeded and sometimes invasive procedures such as biopsies.3 More importantly, reducing false negatives could save lives as well as reduce the cost and difficulty of cancer treatment through early detection.

For more information: www.curemetrix.com

References

1. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early- detection/mammograms/limitations-of-mammograms.html

2. http://ww5.komen.org/BreastCancer/AccuracyofMammograms.html

3. http://content.healthaffairs.org/content/34/4/576.abstract

Related Content

A recent study earlier this year in the journal Nature, which included researchers from Google Health London, demonstrated that artificial intelligence (AI) technology outperformed radiologists in diagnosing breast cancer on mammograms
Feature | Breast Imaging | April 06, 2020 | By Samir Parikh
A recent study earlier this year in the journal Nature,
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Feature | Breast Density | April 03, 2020 | By Dayna Williams M.D., Shivani Chaudhry, M.D., and Laurie R. Margolies, M.D.
Breast cancer is the most common cance
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus

Getty Images

Feature | Coronavirus (COVID-19) | April 02, 2020 | Jilan Liu and HIMSS Greater China Team
Information technologies have played a pivotal role in China’s response to the novel coronavirus...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 the company is now offering a suite of AI solutions Vuno Med-LungQuant and Vuno Med-Chest X-ray for COVID-19, encompassing both lung X-ray and computed tomography (CT) modalities respectively all at once
News | Artificial Intelligence | April 02, 2020
April 2, 2020 — In the face of the COVID-19 pand
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 The Chinese start-up company Infervision launches its AI-based solution InferRead CT Lung Covid-19 also in Europe
News | Artificial Intelligence | March 31, 2020
March 31, 2020 — Lung infections generated by the coronavirus can be detected in...